[Intravenous immunoglobulins in hematologic therapy].
The use of intravenous immunoglobulin (IgIV) increased in the last ten years. IgIV are used in three different groups of haematologic pathologies. The first group is formed by the immunodeficiencies: primaries (those that started the use of IgIV) and secondaries (from immunosuppressive agents and from deficit accessories of Ig). The second group is that of autoimmunity of the blood corpuscular elements (ITP, autoimmune neutrocytopenia and autoimmune haemolytic anaemias). The third group is represented by thrombotic thrombocytopenic purpura. The right protocol and the optimal formulas of the dosages of IgIV are still to be tested. The same applies to its action mechanisms and its potential utilization in other diseases.
Giovanelli
E
E
Primario Divisione Ematologica, Ospedale Mauriziano di Torino.
D001327:Autoimmune Diseases / Q000628:therapy; D006402:Hematologic Diseases / Q000628:therapy*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy; D011697:Purpura, Thrombotic Thrombocytopenic / Q000628:therapy
D016756:Immunoglobulins, Intravenous
Le immunoglobuline endovenose in terapia ematologica.